Tag: Rubius Therapeutics
Vacant Rubius property generating interest after 1 year on market
SMITHFIELD – Despite remaining vacant one year after its purchase by Boston-based The Davis Cos., the former Rubius Therapeutics facility in Smithfield has attracted...
Boston firm acquires Rubius Therapeutics facility
SMITHFIELD – Following significant layoffs in the fall, Rubius Therapeutics Inc. has sold its biomanufacturing facility to Boston-based company The Davis Cos.
The purchase includes...
PBN’s most-read stories of 2022
From developments with the potential to reshape the landscape of Providence and a steady stream of million-dollar home sales across Rhode Island, to ongoing...
Rubius to lay off about 70 R.I. employees, considering sale of...
SMITHFIELD – Rubius Therapeutics plans to lay off 75% of its workforce, including about 70 of its 101 employees in Rhode Island, and is...
Rubius Therapeutics reports $196.5M loss in 2021
PROVIDENCE – Rubius Therapeutics Inc. on Friday reported a loss of $196.5 million in 2021, or $2.23 per diluted share.
The clinical-stage biopharmaceutical company, which...
Rubius Therapeutics ramps up R&D costs, reports $49M loss in Q3
PROVIDENCE – Rubius Therapeutics Inc. reported a $49 million loss in the third quarter, or 55 cents per diluted share, a decline from a...
Rubius Therapeutics logs $50.2M loss in Q2
CAMBRIDGE, Mass. – The clinical-stage biopharmaceutical company Rubius Therapeutics Inc. reported a loss of $50.2 million in the second quarter, or 56 cents per...
Rubius Therapeutics posts $42.3M loss in Q1
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a $42.3 million loss in the first quarter of 2021, or 51 cents per diluted share, the...
Rubius Therapeutics reports $167.7M loss in 2020
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported Tuesday a loss of $167.7 million in 2020, or $2.08 per diluted share.
The clinical-stage biopharmaceutical company, which...
Rubius Therapeutics reports $40.9M loss in Q3
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a loss of $40.9 million, or 51 cents per diluted share, in the third quarter.
The clinical-stage biopharmaceutical...
- Featured Event -
